MaaT Pharma MaaT034 preclinical data at AACR shows potential in solid tumours

MaaT presented new preclinical data for MaaT034 (donor-independent co-cultured microbiome therapy) at the American Association for Cancer Research (AACR) conference, being held 25-30 April in Chicago. The results show the potential for microbiome therapies to improve responses in solid tumours when combined with immune checkpoint inhibitors. Results from a phase 2 investigator-initiated placebo-controlled trial of MaaT013 (microbiome therapy, enema formulation) in combination with checkpoint inhibitors Yervoy (anti-CTLA-4) and Opdivo (anti-PD1) in metastatic melanoma is due to report results in 2H25. If positive, this would confirm the pre-clinical data in the robust placebo controlled clinical setting, and would pave the path for MaaT to expand into the larger commercial opportunity of solid tumours. We reiterate our € 17 TP and Buy rating.